Translational Retinal Research and Therapies
نویسندگان
چکیده
منابع مشابه
Translational research on advanced therapies.
Fostering translational research of advanced therapies has become a major priority of both scientific community and national governments. Advanced therapy medicinal products (ATMP) are a new medicinal product category comprising gene therapy and cell-based medicinal products as well as tissue engineered medicinal products. ATMP development opens novel avenues for therapeutic approaches in numer...
متن کاملCell based therapies in retinal diseases
Background Degenerative retinal diseases, including age related macular degeneration, glaucoma, and hereditary retinal dystrophies are major causes of blindness. The principal defect in these diseases is cell loss which is amenable to both cell based neuroprotective and neuroregenerative therapies. To briefly review the lines of research and potential candidates for cell based therapies among ...
متن کاملTargeted therapies in melanoma: Translational research at its finest
The therapeutic landscape for advanced melanoma has expanded in recent years. This expansion has largely been driven by investigational work in melanoma tumor biology and immunology that has been successfully translated to the clinical setting. Molecular evidence generated through benchside experimentation identified BRAF and MEK as key molecular targets in melanoma. This commentary will highli...
متن کاملcell based therapies in retinal diseases
background degenerative retinal diseases, including age related macular degeneration, glaucoma, and hereditary retinal dystrophies are major causes of blindness. the principal defect in these diseases is cell loss which is amenable to both cell based neuroprotective and neuroregenerative therapies. to briefly review the lines of research and potential candidates for cell based therapies among r...
متن کاملBasic and translational research
Weinblatt ME, Bingham CO, Mendelsohn AM, et al. Ann Rheum Dis (2012). doi:10.1136/annrheumdis-2012-201411 1 of 9 and anti-TNF-experienced4 patients with RA when administered monthly via subcutaneous injection. Intravenous administration of golimumab every 12 weeks (q12 weeks) was previously assessed in a phase 3 trial in patients with RA, with persistent disease despite MTX therapy.5 While the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Vision Science & Technology
سال: 2018
ISSN: 2164-2591
DOI: 10.1167/tvst.7.5.8